MGMT promoter hypermethylation in a series of 104 glioblastomas

Marta Mellai, Valentina Caldera, Laura Annovazzi, Adriano Chiò, Michele Lanotte, Paola Cassoni, Gaetano Finocchiaro, Davide Schiffer

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Aim: To evaluate MGMTpromoter hypermethylation as prognostic factor in a retrospective study of 104 cases of glioblastoma multiforme (GBM). Materials and Methods: The O 6-methylguanine-DNA methyltransferase (MGMT) status was evaluated by methylation-specific PCR (MSP), immunohistochemistry and Western blotting analysis in formalin-fixed paraffin-embedded surgical samples. Results: The MGMT gene was found to be methylated in 29 of 101 tumors (28.7%) by MSP, according to the evaluation methods employed. By immunohistochemistry, different categories were identified on the basis of reaction intensity, percentage of positive cells and homogeneous or heterogeneous distribution. MSP did not correlate with immunohistochemistry, with the exception of the category with the highest percentage of positive cells and homogeneity of immunostaining. Western blotting analysis correlated with immunohistochemical findings (Pearson's correlation coefficient r=0268, p=0.0211), but not with MSP. By Kaplan-Meier survival analysis, radiotherapy was a significant prognostic factor (p=0.0001). When uncensored patients alone were considered, MGMT methylation status showed a significant correlation with survival (p=0.026). Temozolomide therapy correlated with survival (p=0.022), but not with MGMT methylation. After multivariate Cox regression analysis, only radiotherapy remained as an independent prognostic factor (p=0.0001). Conclusion: Correlation was inconclusive among MSP, immunohistochemistry and Western blotting analysis, despite the sophisticated score system for the immunohistochemical quantitative evaluation. MGMT expression is a complex event in which many factors beside epigenetic silencing are implicated.

Original languageEnglish
Pages (from-to)219-227
Number of pages9
JournalCancer Genomics and Proteomics
Volume6
Issue number4
Publication statusPublished - Jul 2009

Fingerprint

Methylation
Methyltransferases
Glioblastoma
Polymerase Chain Reaction
Immunohistochemistry
DNA
Western Blotting
temozolomide
Radiotherapy
DNA Methylation
O(6)-Methylguanine-DNA Methyltransferase
Cells
Survival
Kaplan-Meier Estimate
Survival Analysis
Epigenomics
Regression analysis
Paraffin
Formaldehyde
Tumors

Keywords

  • Glioma
  • MGMT
  • Survival
  • Temozolomide

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Cancer Research
  • Biochemistry

Cite this

Mellai, M., Caldera, V., Annovazzi, L., Chiò, A., Lanotte, M., Cassoni, P., ... Schiffer, D. (2009). MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics and Proteomics, 6(4), 219-227.

MGMT promoter hypermethylation in a series of 104 glioblastomas. / Mellai, Marta; Caldera, Valentina; Annovazzi, Laura; Chiò, Adriano; Lanotte, Michele; Cassoni, Paola; Finocchiaro, Gaetano; Schiffer, Davide.

In: Cancer Genomics and Proteomics, Vol. 6, No. 4, 07.2009, p. 219-227.

Research output: Contribution to journalArticle

Mellai, M, Caldera, V, Annovazzi, L, Chiò, A, Lanotte, M, Cassoni, P, Finocchiaro, G & Schiffer, D 2009, 'MGMT promoter hypermethylation in a series of 104 glioblastomas', Cancer Genomics and Proteomics, vol. 6, no. 4, pp. 219-227.
Mellai M, Caldera V, Annovazzi L, Chiò A, Lanotte M, Cassoni P et al. MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics and Proteomics. 2009 Jul;6(4):219-227.
Mellai, Marta ; Caldera, Valentina ; Annovazzi, Laura ; Chiò, Adriano ; Lanotte, Michele ; Cassoni, Paola ; Finocchiaro, Gaetano ; Schiffer, Davide. / MGMT promoter hypermethylation in a series of 104 glioblastomas. In: Cancer Genomics and Proteomics. 2009 ; Vol. 6, No. 4. pp. 219-227.
@article{e0c25421c27749b0be01da9a56f79ef7,
title = "MGMT promoter hypermethylation in a series of 104 glioblastomas",
abstract = "Aim: To evaluate MGMTpromoter hypermethylation as prognostic factor in a retrospective study of 104 cases of glioblastoma multiforme (GBM). Materials and Methods: The O 6-methylguanine-DNA methyltransferase (MGMT) status was evaluated by methylation-specific PCR (MSP), immunohistochemistry and Western blotting analysis in formalin-fixed paraffin-embedded surgical samples. Results: The MGMT gene was found to be methylated in 29 of 101 tumors (28.7{\%}) by MSP, according to the evaluation methods employed. By immunohistochemistry, different categories were identified on the basis of reaction intensity, percentage of positive cells and homogeneous or heterogeneous distribution. MSP did not correlate with immunohistochemistry, with the exception of the category with the highest percentage of positive cells and homogeneity of immunostaining. Western blotting analysis correlated with immunohistochemical findings (Pearson's correlation coefficient r=0268, p=0.0211), but not with MSP. By Kaplan-Meier survival analysis, radiotherapy was a significant prognostic factor (p=0.0001). When uncensored patients alone were considered, MGMT methylation status showed a significant correlation with survival (p=0.026). Temozolomide therapy correlated with survival (p=0.022), but not with MGMT methylation. After multivariate Cox regression analysis, only radiotherapy remained as an independent prognostic factor (p=0.0001). Conclusion: Correlation was inconclusive among MSP, immunohistochemistry and Western blotting analysis, despite the sophisticated score system for the immunohistochemical quantitative evaluation. MGMT expression is a complex event in which many factors beside epigenetic silencing are implicated.",
keywords = "Glioma, MGMT, Survival, Temozolomide",
author = "Marta Mellai and Valentina Caldera and Laura Annovazzi and Adriano Chi{\`o} and Michele Lanotte and Paola Cassoni and Gaetano Finocchiaro and Davide Schiffer",
year = "2009",
month = "7",
language = "English",
volume = "6",
pages = "219--227",
journal = "Cancer Genomics and Proteomics",
issn = "1109-6535",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - MGMT promoter hypermethylation in a series of 104 glioblastomas

AU - Mellai, Marta

AU - Caldera, Valentina

AU - Annovazzi, Laura

AU - Chiò, Adriano

AU - Lanotte, Michele

AU - Cassoni, Paola

AU - Finocchiaro, Gaetano

AU - Schiffer, Davide

PY - 2009/7

Y1 - 2009/7

N2 - Aim: To evaluate MGMTpromoter hypermethylation as prognostic factor in a retrospective study of 104 cases of glioblastoma multiforme (GBM). Materials and Methods: The O 6-methylguanine-DNA methyltransferase (MGMT) status was evaluated by methylation-specific PCR (MSP), immunohistochemistry and Western blotting analysis in formalin-fixed paraffin-embedded surgical samples. Results: The MGMT gene was found to be methylated in 29 of 101 tumors (28.7%) by MSP, according to the evaluation methods employed. By immunohistochemistry, different categories were identified on the basis of reaction intensity, percentage of positive cells and homogeneous or heterogeneous distribution. MSP did not correlate with immunohistochemistry, with the exception of the category with the highest percentage of positive cells and homogeneity of immunostaining. Western blotting analysis correlated with immunohistochemical findings (Pearson's correlation coefficient r=0268, p=0.0211), but not with MSP. By Kaplan-Meier survival analysis, radiotherapy was a significant prognostic factor (p=0.0001). When uncensored patients alone were considered, MGMT methylation status showed a significant correlation with survival (p=0.026). Temozolomide therapy correlated with survival (p=0.022), but not with MGMT methylation. After multivariate Cox regression analysis, only radiotherapy remained as an independent prognostic factor (p=0.0001). Conclusion: Correlation was inconclusive among MSP, immunohistochemistry and Western blotting analysis, despite the sophisticated score system for the immunohistochemical quantitative evaluation. MGMT expression is a complex event in which many factors beside epigenetic silencing are implicated.

AB - Aim: To evaluate MGMTpromoter hypermethylation as prognostic factor in a retrospective study of 104 cases of glioblastoma multiforme (GBM). Materials and Methods: The O 6-methylguanine-DNA methyltransferase (MGMT) status was evaluated by methylation-specific PCR (MSP), immunohistochemistry and Western blotting analysis in formalin-fixed paraffin-embedded surgical samples. Results: The MGMT gene was found to be methylated in 29 of 101 tumors (28.7%) by MSP, according to the evaluation methods employed. By immunohistochemistry, different categories were identified on the basis of reaction intensity, percentage of positive cells and homogeneous or heterogeneous distribution. MSP did not correlate with immunohistochemistry, with the exception of the category with the highest percentage of positive cells and homogeneity of immunostaining. Western blotting analysis correlated with immunohistochemical findings (Pearson's correlation coefficient r=0268, p=0.0211), but not with MSP. By Kaplan-Meier survival analysis, radiotherapy was a significant prognostic factor (p=0.0001). When uncensored patients alone were considered, MGMT methylation status showed a significant correlation with survival (p=0.026). Temozolomide therapy correlated with survival (p=0.022), but not with MGMT methylation. After multivariate Cox regression analysis, only radiotherapy remained as an independent prognostic factor (p=0.0001). Conclusion: Correlation was inconclusive among MSP, immunohistochemistry and Western blotting analysis, despite the sophisticated score system for the immunohistochemical quantitative evaluation. MGMT expression is a complex event in which many factors beside epigenetic silencing are implicated.

KW - Glioma

KW - MGMT

KW - Survival

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=69549111318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69549111318&partnerID=8YFLogxK

M3 - Article

C2 - 19656999

AN - SCOPUS:69549111318

VL - 6

SP - 219

EP - 227

JO - Cancer Genomics and Proteomics

JF - Cancer Genomics and Proteomics

SN - 1109-6535

IS - 4

ER -